Compare NTWK & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTWK | SCYX |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 51.4M |
| IPO Year | 1997 | 2014 |
| Metric | NTWK | SCYX |
|---|---|---|
| Price | $4.08 | $5.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 15.4K | ★ 79.9K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.67 | 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $73,088,687.00 | $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.40 | N/A |
| 52 Week Low | $2.73 | $0.57 |
| 52 Week High | $5.75 | $6.09 |
| Indicator | NTWK | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 57.42 |
| Support Level | $2.94 | $4.65 |
| Resistance Level | $4.53 | $5.56 |
| Average True Range (ATR) | 0.11 | 0.36 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 58.37 | 34.45 |
NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.